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Abstract
It is well known that certain types of pre-malignant lesions can predispose some 
women to increased risk of breast cancer. These certain types of pre-malignant lesions 
are generally classified as high-risk breast lesions. These lesions become invasive 
cancers in about 15% of patients and hence the management and treatment of these 
lesions warrant a significant discussion. There are several categories of these lesions, 
to include atypical hyperplasia of the breast (atypical ductal hyperplasia and atypical 
lobular hyperplasia); carcinoma in situ (ductal carcinoma in situ and lobular carcinoma 
in situ); columnar cell pre-malignant lesions; lobular intraepithelial neoplasia (LIN III); 
radial scar/complex sclerosing lesion; sclerosing adenosis and papillary lesions of the 
breast. These lesions are morphologically, radiologically, histologically and clinically 
heterogeneous and early identification can help to prevent progression to invasive can-
cers. The management of these lesions has been debated internationally for years by 
experts as to the best treatment modality with surgical excision of the lesion often not 
considered necessary. It is thus important to evaluate each patient on an individual 
case-by-case basis. The characteristics of these high-risk breast lesions are further dis-
cussed in this chapter.
Keywords: breast cancer, in-situ carcinoma, atypical hyperplasia, pre-malignant, breast 
lesions, mammogram, breast ultrasound
1. Introduction
Breast cancer is the most common cancer diagnosed in women worldwide [1]. It is the fifth 
most common cause of death from cancer worldwide but is the second most common cause 
of death in developed countries [1]. The mortality rates up to 5 years after diagnosis is higher 
in the less developed countries compared to more developed countries specifically in Europe 
and North America [1]. Breast lesions can be divided into benign or non-proliferative, high 
risk or pre-malignant and invasive or infiltrating breast lesions [2]. Benign or non-proliferative 
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breast lesions are non-cancerous breast lesions that can occur in any anatomical structure of 
the breast and can present symptomatically or as an incidental finding on imaging or his-
tological findings [3]. Types of benign breast lesions include mammary duct ectasia, masti-
tis, fat necrosis, benign cysts, breast abscess, epithelial-related calcifications, non-sclerosing 
adenosis, benign intraductal papilloma, breast haematoma, lipoma, fibroadenoma, periductal 
fibrosis and gynaecomastia (in men) [3]. Invasive breast cancers are a group of heterogeneous 
malignant breast lesions that originate from breast epithelial cells and invade surrounding 
breast tissue as well as having the potential to metastasise via lymphatics and blood to dis-
tant sites [4]. Invasive or infiltrating breast cancers tend to commonly involve the ducts and 
lobules of the breast [4]. These include the invasive ductal carcinoma (IDC) and invasive lobu-
lar carcinoma (ILC), which comprise of around 80 and 10% of the total invasive carcinoma 
types respectively [2]. The other less common types of invasive breast carcinomas (~10% of 
all breast cancers) include medullary, mucinous, tubular, inflammatory, papillary, adenoid 
cystic, apocrine, lymphoma, sarcoma, phyllodes and Paget’s disease of the nipple [2].
This chapter will primarily focus on high-risk or pre-malignant breast lesions. High-risk or 
pre-malignant breast lesions are breast lesions that have the potential to become malignant 
but the risk and time to progression is variable in each lesion [5]. These lesions are usually 
asymptomatic and are detected incidentally on breast imaging in the majority of cases [6]. 
Some of the more proliferative lesions (e.g. DCIS) may present with symptoms [6]. Types 
of high-risk breast lesions include atypical ductal hyperplasia (ADH), atypical columnar 
cell hyperplasia/columnar alteration with prominent apical snouts and secretions (CAPSS), 
ductal carcinoma in situ (DCIS), atypical lobular hyperplasia (ALH), lobular intraepithelial 
neoplasia (LIN III), lobular carcinoma in situ (LCIS), radial scar/complex sclerosing lesion, 
sclerosing adenosis, papillary lesions of the breast and flat epithelial atypia [5, 7].
In an attempt to classify breast lesions to determine the lesions that have a high relative risk 
of becoming malignant, Page categorised breast lesions based on morphological features into 
four categories [20]. The first category included non-proliferative lesions (no increased risk) 
such as florid adenosis, apocrine change, mild epithelial hyperplasia of usual type and duct 
ectasia [20]. The second category included epithelial proliferative lesions without atypia (1.5–2 
times increased risk) such as moderate/florid hyperplasia of usual type or papillomatosis [20]. 
The third category consists of atypical hyperplastic lesions (4–5 times increased risk) such as 
ADH and ALH [20]. Finally the fourth category is lesions considered to be carcinoma in situ 
and high-risk lesions (8–10 times increased risk), which include DCIS and LCIS [20]. This 
criterion is still referred to by pathologists to classify breast lesions based on their histology.
2. Types of high-risk breast lesions
2.1. Atypical hyperplasia of the breast (ADH and ALH)
2.1.1. Atypical ductal hyperplasia (ADH)
Atypical ductal hyperplasia (ADH) is a pre-malignant lesion of the breast that carries a four to 
five times increased risk of developing carcinoma of the breast in the general population [8]. 
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Several previous studies showed that the cumulative risk for developing invasive breast can-
cer is approximately 13% over a duration of up to 25 years post diagnosis of ADH [9–11]. This 
risk is doubled in women with a family history of breast cancer in a first-degree relative [8]. 
Over half of the breast cancers that develop from ADH are moderate or high grade and usu-
ally involve the ducts on histology [11]. Of the invasive breast cancers, 25% tend to be node-
positive and over 80% being oestrogen receptor (ER) positive [11]. These cancers are also more 
likely to develop on the same breast that had ADH as opposed to the contralateral side [11]. 
Menopausal status of patients with ADH was also considered in determining the risk of devel-
oping invasive cancer. Some authors report that the risk is greater in premenopausal women 
with atypical hyperplasia [12]; while others suggested that this may only be relevant in ALH 
but not in ADH and that this risk was modified once the patient approaches menopause [13]. 
A more recent study done in 2017 showed a reduction of the cumulative risk to two times the 
risk of developing invasive breast cancer 10 years after the diagnosis of ADH [14]. This study 
was performed on a cohort of 955,331 women of which 2785 were diagnosed with ADH fol-
lowing either a core needle biopsy (CNB) or excisional breast biopsy (EBB) [14]. The results 
from this study showed a reduction in the risk of developing invasive breast cancer at 10 years 
following an ADH diagnosis to 5.7–6.7% [14].
It has been shown that ADH and DCIS have very similar characteristics histologically. 
Often it has been difficult to distinguish between ADH and DCIS especially on smaller tis-
sue samples such as those obtained from fine needle aspiration cytology (FNAC) or core 
needle biopsy (CNB) [15]. Hence, the most accurate method for diagnosis is by excisional 
biopsy of the entire lesion [15]. ADH is described histologically as lesions with structur-
ally complex patterns formed from the expansion and filling of breast ducts with the pro-
liferation of monotonous epithelial cells and the presence of secondary lumens [16]. Its 
features are very similar to DCIS on radiological investigation and can be difficult to dis-
tinguish using imaging and CNB only [16]. On mammography, a cluster of calcifications 
may represent ADH [17]. Atypical hyperplasia diagnosis is confirmed in up to 10% of all 
the CNB performed on these calcifications [17]. Its features are similar to DCIS on ultraso-
nography and appears as a mildly hypoechoic microlobulated mass with normal acoustic 
transmission [18]. There is also a higher rate for an inaccurate diagnosis by using only 
an ultrasound-guided CNB instead of an excisional biopsy [19]. Studies have shown that 
more than half of the ADH diagnosed using this technique yielded a malignant pathology 
on surgical excision [19].
Page had previously categorised breast lesions based on morphological features into four 
categories based on the risk of developing malignancy [20]. To assess if these categories of 
diagnosing pre-malignant breast lesions are reproducible, a study was performed evaluating 
the inter-observer variation in the diagnosis of various pre-malignant ductal breast lesions 
including non-atypical ductal hyperplasia, ADH and DCIS [21]. Pathologists in the study fol-
lowed strictly to Page’s standardised criteria [20]. The study concluded that there were no 
significant inter-observer differences in forming the diagnosis of these lesions and if adhered 
to, the standardised diagnosis criteria can be a useful tool [20, 21]. However, despite these 
classifications, some pathologists argue that the interpretation of ADH and DCIS lesions are 
still subjective as histologically these lesion are very similar despite being quantitatively dif-




ADH is usually diagnosed with a CNB; however, due to the small quantity of samples obtained, 
a DCIS or invasive carcinoma are unable to be excluded as previous studies have shown that 
ADH may exist alongside DCIS and invasive cancer [23]. A study done by Gadzala et al. con-
firmed this notion as they found in 36 patients that had a diagnosis of ADH on stereotactic CNB, 
17 patients (47%) were confirmed to have DCIS or IDC after EBB was performed [23]. Therefore, 
excisional breast biopsy (EBB) was found to be the best option to confirm the ADH diagnosis 
and outrule ductal carcinoma [23]. In contrary, some researchers believed that it was unwar-
ranted to perform EBB when the more improved techniques of CNB used larger gauge needles 
(9-, 11- or 14-gauge) and has the potential to diagnose as well as treat ADH without the need 
for EBB [24]. They suggested that ADH with fewer than three foci and the complete removal of 
calcifications on biopsy was adequate and prevented the need for EBB in some patients, which 
has some cosmetic deformity consequences as well as the unnecessary risk of undergoing a 
surgical procedure [24]. Nevertheless, the clinical recommendation for the definitive manage-
ment of ADH still remains as EBB despite the improved CNB techniques as the percentage of 
underestimation of cancer after an ADH diagnosis can carry a risk of over 10% [11, 15].
2.1.2. Atypical lobular hyperplasia (ALH)
Another type of atypia that can be found in the breast is atypical lobular hyperplasia (ALH). 
Similar to ADH, its risk of developing future breast cancer is high (4–5 increased risk com-
pared to women with no atypia), hence ALH is also categorised as a pre-malignant breast 
cancer [8]. Page et al. had previously reported that the high risk may be due to the involve-
ment of ducts in some ALH lesions; however, if there is no ductal involvement, the risk is 
reduced to 2.7 [25]. The risk of developing breast cancer with a prior ALH lesion is higher in 
pre and perimenopausal women (aged 46–55) and reduced in the postmenopausal cohort, 
conversely, menopausal status has no bearing on ADH risk of breast cancer as both pre and 
post menopausal women have similar risk scores [13]. The cumulative risk for developing 
invasive breast cancer is approximately 18% over a duration of up to 25 years post the diag-
nosis of ALH, which is higher than the risk seen with ADH [9–11]. Previous studies have 
also shown that ALH tend to develop into moderate or high grade breast cancers and has 
an increased risk when associated with a strong positive family history of breast cancer as 
similarly observed in patients with ADH diagnosis [11]. ALH has not only been associated 
with the occurrence of future ipsilateral breast cancer but also with contralateral breast 
cancers [26].
ALH is usually asymptomatic and may be found incidentally using breast imaging; however, 
the majority of ALH are found as an association to mass lesions like fibroadenomas, radial 
scars, ADH, intraductal papillomas, pleomorphic LCIS or DCIS following a CNB [26]. If seen 
solitarily, these lesions appear as clustered calcifications and can be difficult to diagnose using 
the imaging modality alone as its characteristics on a mammogram are similar to other pre-
malignant breast conditions [26].
ALH and LCIS have morphologically similar findings and have been termed collectively 
as lobular neoplasia (LN); however, they differ primarily based on the filling of the lobular 
unit and the degree of proliferation [27]. The histology of ALH obtained from either a CNB 
Breast Imaging52
or EBB (if associated to another mass lesion) shows the filling of the acini in the lobular unit 
with monotonous, small, round, cuboidal or polygonal cells with a loss of acinar lumens 
[16]. The diagnosis of ALH can be obtained following Page’s criteria based on the morphol-
ogy of breast lesions [20]. ALH falls into the third category, which also consists of ADH 
[20].
Multiple studies have been carried out to determine the most suitable management option for 
ALH. The diagnosis of ALH was made using stereotactic CNB or EBB if another pre-malignant 
lesion was present [16]. The perplexing issue with ALH is whether the need for management 
via a surgical excision is justified when it presents on its own in a CNB specimen or if it pres-
ents alongside a benign lesion on an EBB sample. The management of ALH diagnosed on CNB 
has remained controversial as there are conflicting opinions. A study performed by Bauer et al. 
divided the diagnosis of LN observed into three groups coexisting with other breast pathologies, 
which comprised of DCIS or invasive cancer (Group 1), ADH, phyllodes tumour, radial scar or 
intraductal papilloma (Group 2) and benign fibrocystic changes (Group 3) [28]. They concluded 
that LN in the absence of breast cancer or pre-malignant conditions (Group 1 and 2) do not need 
EBB [28]. Other authors had similar recommendations as patients with ALH alone or in associa-
tion with benign breast disease were not associated with breast carcinoma (<8% associated with 
cancer) and were not deemed high risk; hence, the residual microcalcifications did not require a 
further EBB [29]. In addition to this, it was suggested that if strict radiographic-pathologic cor-
relation and histologic criteria are adhered to, then the patients who do not require EBB, should 
be closely monitored with regular clinical follow-up and breast imaging (mammogram, ultra-
sound, MRI breast) [26, 30]. Another study contradicted this recommendation as they found 
that 17% of the patients with LN developed either DCIS or invasive carcinoma [31]. Of the ALH 
cohort of 20 patients, 2 developed DCIS, hence only the LCIS cohort developed invasive carci-
noma [31]. Nevertheless, the group suggested that due to the high percentage of patients with 
cancer after the diagnosis of LN, an EBB is warranted [31]. Supporting this recommendation, 
other studies performed using CNB also found that LN lesions had a higher risk for develop-
ing breast cancer and an underestimation of 8–19% if CNB alone was performed without a 
completion EBB [32, 33]. To further stratify the exact criteria of ALH or LCIS (LN lesions) that 
warranted surgical excision, histologic findings of these lesions with more than 1 lobule per core 
involvement were considered to be diffuse lobular neoplasia while those with 1 or less lobules 
affected in each core (focal lobular neoplasia) did not require full excision [34]. In summary, 
ADH and ALH are radiologically difficult to diagnose as they have features similar to DCIS and 
LCIS respectively and thus are best diagnosed and managed by excisional breast biopsy (EBB).
2.2. Carcinoma in situ of the breast (DCIS and LCIS)
2.2.1. Ductal carcinoma in situ (DCIS)
Ductal carcinoma in situ (DCIS) are pre-malignant breast lesions that can present both symp-
tomatically and asymptomatically as an incidental finding on breast imaging. It accounts for 
up to 30% of breast cancer lesions detected on mammography [35]. These numbers have risen 
significantly following the introduction of screening mammography as compared to previous 




clinically due to symptomatic DCIS [6, 35]. It represents a premalignant proliferation of malig-
nant epithelial cells in the lumen of the breast ducts that have not invaded the basement mem-
brane and retains its myoepithelium layer [36]. DCIS may present with symptoms of a palpable 
breast lump, nipple changes and discharge or asymptomatically for smaller sized lesions seen 
on mammography, which has been associated with a higher risk for the development of inva-
sive carcinoma and treatment failure [6, 37]. The risk of invasive cancer in patients diagnosed 
with DCIS on CNB is 11-fold and vary from 17 to 50% depending on the type of DCIS lesion 
as the invasive cancers tends to occur in the same location as the DCIS lesion [38, 39]. DCIS is 
associated with similar risk factors to that of invasive breast cancer such as increasing age (peak 
at postmenopausal age), family history of breast cancer, nulliparity or late first pregnancy after 
the age of 30 and the use of hormone replacement therapy [40].
Radiologic findings account for the majority of DCIS detection. The majority of DCIS lesions 
appear as microcalcifications on mammography [41]. However, they can also present as cir-
cumscribed masses or focal nodular patterns [41]. Screening mammography has led to the early 
diagnosis and investigation of breast cancer lesions. The early implementation of the appro-
priate management of breast cancer has reduced mortality rates by 30% [42]. This is relevant 
in the case of DCIS lesions as a large percentage of the higher grade lesions have potential to 
become invasive and early diagnosis and management is key to reduce this risk [42]. A focused 
ultrasound can also be carried out once a lesion is detected on mammography to further evalu-
ate the characteristics of the lesion and can aid in the CNB of the lesion [43]. Typical findings 
representing DCIS on ultrasound include features of a microlobulated irregular mass with no 
acoustic shadowing [43].
As mentioned previously, DCIS and ADH have similar morphology [15]. However, DCIS lesions 
are more proliferative and can be diagnosed based on CNB [44]. DCIS are localised lesions that 
usually present in one quadrant of the breast and can be as larger as 5 cm in size [44]. It can be 
classified based on its size, nuclear grade, architectural subtype and the presence of necrosis fol-
lowing the 2009 College of American Pathologists/American Society of Clinical Oncology pro-
tocol [45]. The nuclear grades are subdivided into low (Grade I), intermediate (Grade II) or high 
grade (Grade III) [45]. High grade DCIS is comprised of proliferative large pleomorphic cells with 
abundant normal and abnormal mitoses [36]. Intermediate grade DCIS have similar characteris-
tics of both high and low grade DCIS with an intermediate degree of pleomorphism [36]. They 
tend to present more commonly as a solid cribiform pattern [36]. Low grade DCIS has small cells 
that are in a uniform pattern [36]. Architectural subtypes include comedo, Paget’s disease of the 
nipple, cribriform, micropapillary, papillary and solid patterns (listed in increasing order towards 
a higher grade subtype of DCIS) [45]. DCIS lesions was also found to have varying risk of devel-
oping invasive breast cancer based on genetic alterations and receptor status of the lesion with a 
majority of lesions exhibiting ER positivity on immunohistochemistry staining [37, 44]. Palpable 
DCIS lesions were more commonly associated with negative ER and PR status, which confirms its 
association to a higher grade DCIS and leading to more aggressive phenotype compared to DCIS 
found incidentally on screening [37].
As with other pre-malignant disease of the breast, the diagnosis of DCIS warrants further man-
agement with either surgery and/or other adjuvant treatments due to its nature to progress to 
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invasive malignancy [46]. Multiple trials have been carried out to determine the effectiveness 
of these treatments in the prevention of recurrence after DCIS diagnosis [46]. The options for 
the surgical management of DCIS consist of mastectomy of the affected breast or breast con-
serving surgery such as wide local excision (WLE) [46]. Suitability for either type of surgery 
is based on the grade of the lesion and presence of microinvasion, the patient’s age at diag-
nosis and pre-existing co-morbidities (life expectancy) as these may influence the decision to 
perform a more definitive surgery like mastectomy instead of WLE due to the risk of having 
to re-excise the margins and the chance of local recurrence [46]. Rutter et al. reported on the 
increasing use of mastectomy as a treatment of DCIS especially in patients with higher grade 
DCIS and younger age [47]. This was due to the  increased risk of recurrence and develop-
ment of invasive breast cancer. Other authors have reported the effectiveness of nipple-sparing 
mastectomy in comparison with mastectomy whereby the probability of local recurrence was 
similar and low in the case of DCIS treatment [48]. However, these results were not similarly 
replicated favourably when the breast conserving treatment of DCIS was used as a solitary 
treatment modality. The RTOG 9804 trial was conducted to evaluate the effectiveness of breast 
conserving surgery (BCS) with or without adjuvant radiotherapy in patients diagnosed with 
low or intermediate risk DCIS on CNB [49]. Results showed a low risk for recurrence with BCS 
alone at 6.7%; however, this was significantly lower in the adjuvant radiotherapy arm at 0.9% 
recurrence risk [49]. This opened up the possibility of DCIS subtype with good prognosis to 
be considered for BCS treatment alone without further adjuvant therapy; however, the authors 
concluded that a longer follow-up time of more than 7 years was required to give more repro-
ducible results as the BCS and adjuvant radiotherapy cohort had much better response [49]. 
In contrary to this, other studies have not yielded promising results as patients treated with 
BCS alone had recurrence rates of approximately 14–16%, despite the stratification of patients 
into the low risk DCIS category [50, 51]. Conflicting evidence has been reported regarding the 
need for sentinel lymph node biopsy (SLNB) in the treatment of DCIS. Some studies suggest 
that SLNB should not be part of the standard surgical treatment of all subtypes of DCIS as 
the percentage of positive SLNB range from 1 to 22% with majority of the studies reporting a 
lower percentage of positive findings, hence rendering it unnecessary [52]. Furthermore, some 
authors argue that performing a SLNB in these patients could disrupt the diagnosis of future 
lymphatic spread in the case where invasive carcinoma occurs [53]. The general consensus sur-
rounding the addition of SLNB as part of the surgical treatment of DCIS is to be only reserved 
for those lesions with high grade of DCIS exhibiting microinvasion, large lesions of more than 
5 cm in size, lesions treated with mastectomy and DCIS subtypes with high risk of developing 
invasive cancer [52, 53].
2.2.2. Lobular carcinoma in situ (LCIS)
Lobular carcinoma in situ (LCIS) is similar in histology to ALH; however, it is more extensive 
and proliferative compared to ALH [27]. It is on the higher spectrum of lobular neoplasia 
(LN) [27]. LCIS lesions are usually diagnosed incidentally via breast imaging such as through 
mammographic screening or are detected incidentally as part of a CNB or an EBB for another 
breast lesion diagnosis [54]. LCIS is a pre-malignant lesion that has a 15% risk of developing 




of developing invasive carcinoma on the contralateral breast (mostly ILC) [27, 55, 56]. Its 
estimated incidence is varied between 0.5 and 3.8% as it is most often overlapped with other 
premalignant or invasive lesions in the breast [57–59]. The risk of DCIS or invasive carcinoma 
after the diagnosis of LCIS is 17% at 15 years post diagnosis of LCIS with a relative risk of 
8–10 [59]. Similarly to ALH, LCIS may be affected by menopausal status. Its incidence was 
observed to be higher in premenopausal women with only 10% incidence in postmenopausal 
women, suggesting it may be affected by reproductive history such as age at the birth of first 
child and ovarian function status [8, 60].
Due to the majority of LCIS being detected incidentally on CNB, it is difficult to characterise its 
possible findings on breast imaging. A retrospective study evaluated the appearance of LCIS 
on breast imaging after the diagnosis was confirmed on CNB in an attempt to define the char-
acteristics of LCIS [61]. They described the mammographic findings of LCIS as micro calcifica-
tions [61]. Choi et al. used ultrasound imaging to characterise the feature of LCIS and described 
it as ill-defined, asymmetrical, elongated or round lesions with hypoechogenicity [62].
Histological findings of LCIS are well defined on CNB. LCIS morphology consists of type A 
and B cells [27]. The type A cells have a smaller sized nuclei compared to the larger and more 
pleomorphic type B cells that are usually polygonal, cuboidal or round shaped [27]. These 
cells fill and expand more than half of the acini in the lobular unit with loss of central lumina, 
which differentiates it from the features of ALH [27, 61]. There has been an ongoing debate 
whether CNB is sufficient to diagnose LCIS without further EBB. Murray et al. performed a 
prospective study that investigated the underdiagnoses rate of LN (LCIS and ALH) in samples 
obtained from their institution over 5 years [63]. When there was radiologic and histologic dis-
concordance, 50% of samples diagnosed as LCIS by CNB turned out to be DCIS on EBB [63]. 
However, when there is radiologic and histologic concordance, there were no underdiagnosed 
LCIS lesions by CNB [63]. They compared their results with previous studies and discovered 
that the underdiagnoses risk of DCIS or invasive carcinoma in samples that had radiologic and 
histologic disconcordance is significant in ~38–67% of CNB samples diagnosed as LCIS [63].
The management of LCIS is another controversial issue due to its low incidence and lack 
of distinguishing mammographic findings, as well as its incidental co-diagnosis with other 
breast lesions such as DCIS and IDC [58, 59]. Conflicting opinions have risen with some indi-
cating that surgical excision is unnecessary, while others disagree and recommend the exci-
sion of LCIS is crucial to prevent future development of invasive carcinoma. Nagi et al. agreed 
with the recommendation that type A cell LCIS lesions should be treated conservatively. The 
reasoning is that the cohort of patients with this type of lesion, who did not have surgical 
excision, did not develop progressive disease up to 8 years of follow-up [26]. The authors 
rationale was that as long as strict criteria were followed histologically and close monitoring 
were performed radiologically, surgical excision did not provide further benefit in these type 
A lesions [26]. The type B cell LCIS lesions have poorer prognosis compared to type A, hence 
will require surgical excision [26]. Similar to the management of ALH, lesions diagnosed, as 
LCIS also did not require surgical excision unless associated or is adjacent to other co-existing 
more aggressive premalignant or malignant breast lesions or in the case where there is dis-
cordance between radiologic and histologic diagnosis [28]. In more aggressive forms of LCIS 
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that can present in the contralateral breast, some studies have recommended the option to 
manage LCIS by bilateral prophylactic mastectomies as part of a risk reduction surgery [64]. 
However, the decision to follow through with these surgeries required meticulous discussion 
with a multidisciplinary team (MDT) to assess the patient’s risk of future carcinoma and the 
best management plan for the patient [64].
2.3. Columnar cell pre-malignant lesions of the breast
Types of columnar cell pre-malignant lesions of the breast include columnar alteration with 
prominent apical snouts and secretions (CAPSS; also known as columnar cell lesions: CCL) 
and flat epithelial atypia (FEA; also known as CCL with atypia) [65]. Fraser et al. described a 
type of breast lesion that had similar features on imaging to ADH and DCIS [66]. Although the 
lesion on imaging did not appear benign, it could not be classified specifically as either ADH 
or DCIS on histology as it lacked some features that can confirm these diagnoses [66]. These 
spectra of lesions were described as architecturally complex lesions that exhibited columnar 
epithelial cells with prominent apical cytoplasmic snouts and intraluminal secretions, which 
may or may not have nuclear atypia lining the terminal duct lobular unit (TDLU) [66]. This 
group of lesions were therefore named as columnar alteration with prominent apical snouts 
and secretions (CAPSS) [66]. CAPSS lesions lie on a spectrum depending on the atypia of 
the cells and were routinely diagnosed on ultrasound-guided CNB [67]. Studies have shown 
that CAPSS lesions with atypia closely resembled DCIS and had a higher risk of associa-
tion with invasive cancer when compared to CAPSS lesions without atypia [67]. CAPSS and 
FEA lesions are described as clustered microcalcifications that may have amorphous or fine 
pleomorphic features located in the TDLU on mammography [68]. Again, these features are 
similar to other pre-malignant disease such as ADH and DCIS, hence it is difficult to diagnose 
without a CNB [68]. FEAs are observed histologically as dilated basophilic acini, which con-
sists of layers of cuboidal to columnar epithelial cells with low-grade atypia on cytology and 
distended TDLUs [65, 69].
The presence of CAPSS in the breast was found to increase the risk of breast cancer due to 
its co-occurrence with other proliferative breast lesions such as DCIS [70]. However, these 
lesions independently did not confer a high risk of developing breast cancer [71]. FEAs have 
also been associated with an approximately 20% risk of developing breast cancer and a high 
underestimation rate for malignancy when diagnosed on CNB due to its similar co-existence 
with other pre-malignant lesions such as ADH and DCIS [72].
The suggested clinical recommendation for the management of columnar cell pre-malignant 
lesions of the breast is EBB for both CAPSS and FEA based on radiographic and histologic 
correlations [67, 72, 73].
2.4. Papillary lesions of the breast
Papillary lesions of the breast are composed of benign and malignant types. The papilloma-
tosis of the breast and atypical papilloma lesions may be considered premalignant due to its 
association to the development of breast cancer [74]. Pre-malignant papilloma lesions can be 
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associated with calcifications on mammogram and appear as a homogeneous solid or intra-
cystic lesion that is complex on ultrasound [74]. Clinically, patients with this disease may pres-
ent with symptomatic findings such as a breast mass or nipple discharge [74]. Histologically, 
breast papilloma is described as clusters of epithelium in the ducts that develop into branch-
ing papillae, which protrude into the lumen [75]. Due to the varying spectrum of pathological 
findings seen in the papilloma disease of the breast, it is difficult to distinguish between true 
benign and malignant or premalignant lesions. Multiple studies have shown that the diag-
nostic technique using either FNA or CNB may be inaccurate as benign findings were often 
either co-existing with premalignant lesions or were underestimated [75, 76]. The suggested 
management of breast papillomas diagnosed on FNA or CNB is for active surveillance if there 
is no atypia and no discordance between imaging and histologic findings [74]. When there is 
doubt on biopsy or the presence of high-risk papilloma lesions then an EBB is warranted [74].
2.5. Radial scar/complex sclerosing lesion
A radial scar or complex sclerosing lesions of the breast are considered to be pre-malignant 
breast lesions due to its common association with other more proliferative lesions leading 
to its increase in breast cancer risk [77]. On mammography, a radial scar/complex sclerosing 
lesion is described as the presence of radiolucency in the centre of the lesion with spicules that 
are longer compared to malignant lesions. There is also the presence of radiating radiolucent 
linear structures and the absence of macrocalcifications [77]. Histologically, radial scars have 
a fibroelastic core with entrapped ducts and variable surrounding benign epithelial features; 
however, it can also be associated with atypia usually at the edges of the lesion [78]. The term 
radial scars was given to lesions smaller than or equal to 1 cm while the term complex scleros-
ing lesions is larger than 1 cm [78]. There have been various opinions among pathologists and 
surgeons regarding the most appropriate management of radial scars. Some suggest that a 
large gauge CNB was adequate to sample radial scars and there was no need for EBB as long 
as there is no atypia and the radiology and histology correlate [79]. However, other authors 
still classify radial lesions as high-risk lesions and EBB is the recommend management [79].
3. Adjuvant therapies for the treatment of high-risk breast disease
Adjuvant therapies have been considered in an attempt to reduce the risk of breast cancer fol-
lowing the diagnosis of a pre-malignant breast lesion via CNB or EBB. Several trials have been 
conducted to determine if adjuvant radiotherapy and/or endocrine therapy may be useful as 
a measure to reduce this risk [80].
Trials involving the use of adjuvant radiotherapy were performed on pre-malignant carci-
noma in situ lesions, predominantly, DCIS. Adjuvant radiotherapy used in a study involv-
ing patients with BCS following a DCIS diagnosis, yielded promising results as there was 
a significant risk reduction compared to the control group especially in the postmeno-
pausal patient cohort [81]. A meta-analysis carried out by the Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) evaluating the results from four randomised clinical trials 
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involving adjuvant radiotherapy in the management of DCIS showed that radiotherapy after 
BCS was successful in reducing the absolute risk of developing ipsilateral DCIS recurrence 
and invasive breast cancer development by 15% in the 10 year follow-up duration [80]. As 
similarly seen in the previous study, a greater risk reduction was seen in postmenopausal 
women and that radiotherapy did not have a significant effect on the contralateral breast or 
on distant metastatic occurrence [80]. This led to the suggestion that the patients receiving 
adjuvant radiotherapy as part of the BCS treatment of DCIS should be further stratified to 
avoid unnecessary exposure to radiotherapy, which carries its own risks [80]. The EORTC 
10853 Randomised Phase III Trial further confirmed the benefit of adjuvant radiotherapy 
as it reduced the risk of any local recurrences after an EBB of DCIS by almost half (48%) 
after a 15 year follow-up [82]. The treatment of LCIS with adjuvant radiotherapy has not 
been explored to the same extent as DCIS lesions. A small study carried out with 25 patients 
treated for LCIS lesions with lumpectomy and radiotherapy reported promising findings as 
only 1 patient had a local recurrence after a median follow-up of 153 months [83].
Apart from radiotherapy, multiple studies have been performed to explore the effects of 
oral selective oestrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) as 
part of a preventative measure to reduce the risk of developing breast carcinoma as well 
as an adjuvant treatment following EBB or BCS of DCIS lesions [84–86]. The randomised 
International Breast Cancer Intervention Study (IBIS-I) trial was not aimed specifically at 
women with a known diagnosis of DCIS but was targeted for women with an increased risk 
for the development of DCIS and invasive breast cancer [85]. The trial reported the benefit 
of prophylactic tamoxifen in high-risk women leading to a 34% reduced risk of developing 
invasive cancer [85]. The benefit of tamoxifen was also found to outweigh the risk in this 
subset of high-risk patients [85]. Although this study was not investigating the adjuvant 
treatment of DCIS, however, the rationale of this study can still apply to the management 
of this disease. Most patients have a high risk of developing invasive cancer after a DCIS 
diagnosis and may benefit from adjuvant treatment with selective oestrogen receptor mod-
ulators because of the ER positive nature of DCIS. The National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-17 and B-24 randomised clinical trials were performed to 
determine the effectiveness of lumpectomy alone as a surgical treatment of DCIS compared 
to lumpectomy with adjuvant radiotherapy or tamoxifen therapy [86]. The trial focussed on 
the long-term prognosis of DCIS with these various treatment combinations and the risk 
of ipsilateral invasive breast cancer recurrence [86]. The trial reported that the cumulative 
incidence of ipsilateral invasive breast cancer recurrence (15 year follow-up) was 19.4% for 
lumpectomy only compared to 8.9% for lumpectomy plus adjuvant radiotherapy while the 
incidence was 10.0% in the lumpectomy plus radiotherapy combination treatment group 
compared to 8.5% for the combination treatment of lumpectomy plus adjuvant radiother-
apy and tamoxifen [86]. Radiotherapy and tamoxifen therapy were concluded to be effec-
tive as adjuvant treatments to lumpectomy to reduce the risk of tumour recurrence [86]. 
Another prospective cohort study carried out by Thompson et al. over a follow-up period of 
62 months reported similar findings to Wapnir et al. with a reduction of risk in developing 
DCIS recurrence or ipsilateral breast cancer in patients given adjuvant therapy combination 





High-risk breast lesions vary in the degree of risk of developing either in situ carcinoma or 
invasive carcinoma. Multi-observer disparities in histology reporting had previously been a 
concern; however, standardised criteria have been developed to overcome this issue. There is 
a general consensus that radiologic and histologic concordance is important to formulate an 
accurate diagnosis to help direct the appropriate treatment regime. The management of high-
risk breast lesions is rather confusing and needs to be determined by the risk of developing 
invasive breast cancer. Risk reduction strategies for these high-risk breast lesions described in 
this chapter vary from active surveillance to surgical excision in form of an excisional biopsy 
or a mastectomy with or without adjuvant therapies. These strategies are largely influenced 
by the patient and the clinicians’ decisions.
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